Gilead Sciences reported Q2 revenue of $7.80 billion above $7.40 billion consensus, with adjusted loss per share of $6.75 narrower than expected $7.17 loss, driven by Biktarvy revenue of $3.77 billion and Trodelvy revenue of $457 million both beating estimates while Veklury revenue of $23 million missed $98.1 million estimate.
FirstSquawk08/05, 03:08 AM
- Q2 revenue of $7.80 BLN
- $7.40 BLN estimate
- adjusted loss per share of $6.75
- $7.17 loss
Figures as quoted by FirstSquawk
Related assets
Coming up for GILD
Explore next
Latest GILD news
Jin1008/14, 09:47 PM
FirstSquawk08/05, 03:08 AM
Bloomberg07/29, 06:35 PM